Advertisement

Drug Controller clears Psoriasis injection for 'restricted emergency use' to treat COVID-19 patients

Follow The Hawk on Google News+ Follow

Advertisement

New Delhi: India's drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, officials said on Friday.

Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India, Dr V G Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon, for restricted emergency use for the treatment of "cytokine'' release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.

Advertisement

"The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome," an official told PTI.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

"It is already an approved drug of Biocon for treating psoriasis for last many years," the official said.

Written informed consent of each patient is required before the use of this drug, he said.

—PTI

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST